Background
==========

Atrial fibrillation (AF) is a type of arrhythmia that affects millions of people around the world and has increasing prevalence and high mortality \[[@b1-medscimonit-22-3457]\]. Although several risk factors for AF (e.g., sex, age, and hypertension status) have been identified, the underlying etiology requires further research \[[@b2-medscimonit-22-3457]\]. Both aging and the presence of hypertension change the structure of extracellular matrix (ECM) and alter myocardial substrate, which results in an enhanced AF \[[@b3-medscimonit-22-3457]\]. Fibrosis is an important substrate of ECM remodeling in AF because it subsequently changes connexin expression and then influences impulse propagation by interrupting the process of intermyocyte coupling \[[@b4-medscimonit-22-3457]\]. Myofibroblasts and other inflammatory cells are thought to be the main source of the functional and structural changes in cardiac tissues during cardiac fibrosis \[[@b4-medscimonit-22-3457]\].

The TGF-β super-family, which includes the transforming growth factor TGF-β1-3, Bone Morphogenetic Proteins (BMPs), and other actins, is one of the largest groups in which functions and structures of proteins are integrated \[[@b5-medscimonit-22-3457]\]. Many researchers have shown that TGF-β1 induces epithelial mesenchymal transition (EMT), which is an important process in cardiac fibrosis \[[@b6-medscimonit-22-3457],[@b7-medscimonit-22-3457]\]. TGF-β1 acts as an essential mediator and is able to induce EMT and affect ECM expression in many organs and tissues \[[@b5-medscimonit-22-3457],[@b8-medscimonit-22-3457]\]. TGF-β1 binds with the receptors and then induces a multitude of responses, including the up-regulation of mesenchymal-related proteins such as collagen I and α-SMA, along with the down-regulation of intercellular adhesion proteins such as E-cadherin \[[@b9-medscimonit-22-3457]\]. In addition, it has been shown that the effects of TGF-β1 on renal diseases are mediated by canonical transcription factors Smads, especially Smad3 \[[@b10-medscimonit-22-3457]\]. Downstream Smads of TGF-β1, including Smad2 and Smad3, have been analyzed using rat models of myocardial pressure overload, but the mechanisms by which the TGF-β1/Smads pathway in cardiac fibrosis causes AF remain largely undefined \[[@b11-medscimonit-22-3457],[@b12-medscimonit-22-3457]\].

Bone morphogenetic proteins, which belong to the TGF-β super-family, are multifunctional regulators of cell growth, differentiation, and morphogenesis \[[@b13-medscimonit-22-3457]\]. Ghosh et al. revealed that BMP-2 down-regulated biological effects such as DNA synthesis in kidney cells induced by the epidermal growth factor \[[@b14-medscimonit-22-3457]\]. BMP-7 also plays an important role in the EMP process \[[@b15-medscimonit-22-3457]\]. It has been reported that BMP-7 can reverse fibrosis in many diseases affecting organs such as the liver and kidneys \[[@b8-medscimonit-22-3457],[@b15-medscimonit-22-3457],[@b16-medscimonit-22-3457]\]. BMP-7 and TGF-β1 have homologous ligand structures, binding molecules and downstream signaling regulators, which control a balanced EMT \[[@b15-medscimonit-22-3457]\], and BMP-7 might coordinate with cardiac interstitial fibrosis, but little evidence of this has been produced.

TGF-β1 and BMP-7 transfer their signals from cell surface to nucleus through binding with transmembrane kinase receptors (ALK receptors), and their downstream intracellular signaling pathways are mediated by Smad proteins \[[@b13-medscimonit-22-3457]\]. TGF-β1 action is transduced by Smad2 and Smad3, BMP-7 signaling is regulated by Smad1/5/8, and both pathways are mediated by Smad-4 \[[@b17-medscimonit-22-3457]--[@b19-medscimonit-22-3457]\]. Vargha et al. reported that BMP-7 had a reversed EMT process presented as mesenchymal-to-epithelial phenotype in peritoneal mesothelial cells \[[@b20-medscimonit-22-3457]\]. Another study has demonstrated that BMP-7 can antagonize TGF-β-induced EMT of mesothelial cells and reversed peritoneal fibrosis in rats exposed to peritoneal dialysis fluid \[[@b21-medscimonit-22-3457]\]. However, the ability of BMP-7/Smads to prevent TGF-β1-mediated EMT and reverse cardiac fibrosis results from AF has not been assessed.

In the present study we investigated the molecular mechanism of BMP-7/Smad5 in TGF-β-induced fibrosis, which was conducted in cardiac fibroblasts, and then we evaluated the effect of BMP-7 as a treatment of cardiac fibrosis using a rat model.

Material and Methods
====================

Cell culture
------------

Myocardial fibroblasts were separated from SD mice as previously described \[[@b22-medscimonit-22-3457]\]. Cells were characterized by the immunohistochemistry of vimentin and smooth muscle actin (SMA). Isolated cells were cultured in Dulbecco's modified Eagle medium (DMEM) with 10% fetal calf serum (FCS) at 37°C incubator with 5% CO~2~. Myocardial fibroblasts were cultured with TGF-β to induce fibrosis. Cells were treated with TGF-β for 24 h at different concentration levels (10^−8^, 10^−7^, 10^−6^, and 10^−5^ mol/L) to determine the optimal concentration level of TGF-β. As suggested by the dimethylthiahiazo (MTT) assay described below, 10^−6^ mol/L was considered as the optimal concentration. As a result, cells were treated with TGF-β for different times (6 h, 12 h, 24 h, and 48 h) using the optimal concentration level of 10^−6^ mol/L.

Immunohistochemistry and MTT assay
----------------------------------

Immunohistochemical analysis of myocardial fibroblasts was established using the EnVision two-step method as previously described \[[@b23-medscimonit-22-3457]\]. Rabbit polyclonal anti-vimentin and anti-SMA antibody (Zhongshan Biology Company, Beijing) were diluted 1:100 using the diluent. MTT assay was used to assess the proliferation status of myocardial fibroblasts in each group. A total of 3×10^3^ cells were cultured in 96-well plates, incubated for 24 h, and then stained with 0.5 mg/ml MTT for 4 h. Samples were measured at 490 nm by an enzyme-linked immunosorbent assay (ELISA) reader (Synergy HT, BioTek Instruments, Winooski, VT) after supernatant was discarded and 200 μl of dimethylsulfoxide was added to dissolve precipitate.

Lentivirus transduction
-----------------------

A fragment containing Smad3 siRNA or Smad1/5 siRNA was cloned into the pCDH vector and then amplified by polymerase chain reaction (PCR). The pCDH plasmid and other essential plasmids were co-transfected into cells using the Lipofectamine LTX kit (Invitrogen, CA). Viral particles were collected after 48-htransfection.

Treatment of TGF-β, BMP-7 and Lentivirus in cells
-------------------------------------------------

Myocardial fibroblasts were divided into 5 groups: the control group (normal cells); the TGF-β group (cells treated with 10^−6^ mol/L TGF-b for 48 h); the Smad3 siRNA group (cells treated with 10^−6^ mol/L TGF-β for 48 h and then transfected with Smad3 siRNA); the BMP-7 group (cells treated with 10^−6^ mol/L TGF-β for 48 h and then cultured with 0.5 μg/mL recombinant human BMP-7 (rhBMP-7, Prospec, Israel); and the Smad1/5 siRNA group (cells treated with both TGF-β and rhBMP-7 and then transfected with Smad1/5 siRNA).

Animal model
------------

A total of 60 male SD mice weighing 200 to 250 g (purchased from the Laboratory Animal Center of Chinese Medical University) were randomly allocated to the control group (n=10) and model group (n=50). For intentionally establishing the atrial fibrillation model, 1 ml/kg Ach-CaCl~2~ was injected daily into tail veins of mice in the model group and these mice were raised with regular feeding. Mice in the model group were inspected using electrocardiogram after 4 weeks and we randomly selected 40 mice in which atrial fibrillation models were successfully constructed.

We allocated the 50 selected mice (10 in the control group and 40 in the model group) in the experiment to 5 treatment groups: the control group (n=10, abdominal cavities of mice in the control group were injected with 1 ml saline every 2 days); the model group (n=10, abdominal cavities of mice in the model group were injected with 1 ml saline every 2 days); the low-dose BMP group (n=10, abdominal cavity of mice in the model group was injected with 80 μg/kg rhBMP-7 every 2 days); the high-dose BMP group (n=10, abdominal cavity of mice in the model group was injected with 300 μg/kg rhBMP-7 every 2 days); and the Smad1/5 siRNA group (n=10, left atrial of mice in the model group was injected with Smad1/5 siRNA transfected myocardial fibroblasts and then their abdominal cavities were injected with 300 μg/kg rhBMP-7 every 2 days). All mice were inspected on day 28 after treatments were established.

Western blot
------------

Cells and tissues were harvested and lysed using the radioimmunoprecipitation assay (RIPA) buffer. Total protein was separated and calculated by the Bradford method. Then, total protein was denatured in boiling water and transferred onto polyvinylidene fluoride (PVDF) membranes after sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Membranes were blocked in Tris-buffered saline with tween (TBST) with 5% skim milk for 1 h and treated with primary antibodies (against E-cadherin, collagen I, α-SMA, Smad3, pSmad3, Smad1/5, pSmad1/5, 1:800 dilution, Zhongshan Biology Company, Beijing) at 4°C overnight. After membranes were washed, they were incubated with secondary antibodies (horseradish peroxidase-conjugated goat anti-goat, 1:2000 dilution, Zhongshan Biology Company, Beijing). Samples were processed with enhanced chemiluminescence and quantified by Lab Works 4.5 software in which β-actin was set as an endogenous control.

Cardiac function tests
----------------------

Tests of cardiac function were carried out using the echocardiogram assay (ATL-HDI5000) in which ejection fraction (EF), fractional shortening (FS), left ventricular end-systolic dimension (LVESD), and left ventricular end-diastolic dimension (LVEDD) were detected.

Histopathological examination (HE)
----------------------------------

Tissues from the left atria of mice were harvested and treated with 10% formalin. Then, 5-μm-thick paraffin sections were embedded and stained with HE assay. Samples were inspected under a microscope (Motic China Group Co. Ltd) and measured at 5 random sites.

Statistical analysis
--------------------

All statistical analyses were performed with SPSS 18.0 software (Chicago, IL, USA). Data are presented as mean ± standard deviation (SD) for at least 3 experiments. The 2-tailed *t* test or one-way analysis of variance (ANOVA) was used to assess between-group comparisons, and *P*\<0.05 provided evidence of statistical significance.

Results
=======

Cell culture and TGF-β-treated cells
------------------------------------

Cells were spindle-shaped or polygonal under an optical microscope (×400). Vimentin was stained as brown particles and they were evenly distributed in 95% of cell cytoplasm. Immunohistochemistry of SMA showed negative results ([Figure 1](#f1-medscimonit-22-3457){ref-type="fig"}).

Results from MTT assay in TGF-β--treated cells indicated that TGF-β can up-regulate the cell activity of myocardial fibroblasts in a dose- and time-dependent manner ([Tables 1](#t1-medscimonit-22-3457){ref-type="table"}, [2](#t2-medscimonit-22-3457){ref-type="table"}, [Figure 2](#f2-medscimonit-22-3457){ref-type="fig"}). In this experiment, treatment of 10^−6^ mol/L TGF-β for 48 h resulted in a remarkable loss of the cobblestone-like growing appearance along with elongated fibroblast-like morphological features. A fibrosis model of cardiac fibroblasts was established in this control.

TGF-β induced the expression of fibrosis markers by mediating Smad3
-------------------------------------------------------------------

Compared with the control group, the expression level of epithelial marker E-cadherin in the TGF-β group was significantly decreased when expression levels of pSmad3 and mesenchymal markers. including collagen I and α-SMA were up-regulated (all *P*\<0.05, [Table 3](#t3-medscimonit-22-3457){ref-type="table"}, [Figure 3](#f3-medscimonit-22-3457){ref-type="fig"}). Compared with the TGF-β group, the TGF-β + Smad3 siRNA group exhibited significantly higher expressions of E-cadherin as well as down-regulated Smad3, pSmad3, collagen I, and α-SMA expressions (all *P*\<0.05, [Figure 3](#f3-medscimonit-22-3457){ref-type="fig"}), indicating that TGF-β was capable of inducing fibrosis, which was suppressed by silencing Smad3.

BMP-7 antagonized fibrosis of myocardial fibroblasts by mediating Smad1/5
-------------------------------------------------------------------------

Compared with cells with TGF-β treatment, cells in the BMP-7 + TGF-β group had significantly higher expression levels of E-cadherin and pSmad1/5 and lower expression levels of pSmad 3, collagen I, and α-SMA (all *P*\<0.05, [Table 4](#t4-medscimonit-22-3457){ref-type="table"}, [Figure 4](#f4-medscimonit-22-3457){ref-type="fig"}), suggesting the protective effects of BMP-7 on fibrosis induced by TGF-β. After transfection of Smad1/5 siRNA, expression levels of pSmad3, Smad1/5, pSmad1/5, E-cadherin, collagen I, and α-SMA for cells in the Smad1/5 siRNA group were ranked between the TGF-β and BMP-7 group. We found significant differences in the expressions of E-cadherin, collagen I, α-SMA, and pSmad1/5 among these groups (all *P*\<0.05, [Figure 4](#f4-medscimonit-22-3457){ref-type="fig"}), indicating that the effect of BMP-7 was inhibited by Smad1/5 siRNA.

Results of cardiac function tests
---------------------------------

As shown in [Figure 5](#f5-medscimonit-22-3457){ref-type="fig"}, mice in the model group, which were treated with Ach-CaCl~2~, exhibited obvious atrial ectopy. Therefore, the atrial fibrillation model was successfully established and 40 mice in the model group were randomly selected for experimental purposes.

After mice were treated with BMP-7 and Smad1/5 siRNA, all mice in the 5 groups were tested by several cardiac functions: EF, FS, LVESD, and LVEDD. There were significant differences in cardiac functions between any of the 2 groups in the control, model, low-dose BMP-7, or high-dose BMP-7 group (all *P*\<0.05, [Table 5](#t5-medscimonit-22-3457){ref-type="table"}, [Figure 6](#f6-medscimonit-22-3457){ref-type="fig"}). The control group exhibited the most robust cardiac functions, whereas the model group had the largest loss of cardiac functions. Cardiac functions in the low-dose BMP-7 group and high-dose BMP-7 group were ranked between the control and model group. Both the low-dose BMP-7 and high-dose BMP-7 groups exhibited higher EF and FS compared with the model group. Apart from that, the improvement in cardiac functions was more significant in the high-dose BMP-7 group in comparison to the low-dose BMP-7 group. For the Smad1/5 siRNA group, in which mice were treated with both high-dose BMP-7 and Smad1/5 siRNA, results were significantly lower compared with the control group, the low-dose BMP-7 group, and the high-dose BMP-7 group (all *P*\<0.05, [Figure 6](#f6-medscimonit-22-3457){ref-type="fig"}). Results of the Smad1/5 siRNA group were similar to those in the model group and they were ranked between the model group and the low-dose BMP-7 group.

The above evidence suggests that Ach-CaCl~2~ treatment can interfere with cardiac functions of mice and that BMP-7 plays a protective role in cardiac functions. On the other hand, Smad1/5 siRNA inhibited the protective effect of BMP-7. These results were further assessed by histopathological examination of left atrium tissues in model mice. As shown in [Figure 7](#f7-medscimonit-22-3457){ref-type="fig"}, tissues in the control group exhibited neatly arranged and uniformly dyed muscle fibers, whereas muscle fibers of tissues in the model group were broken and disorganized in the white fibrosis area.

The expression of fibrosis markers in cardiac tissues
-----------------------------------------------------

We detected the expression level of fibrosis markers and related signaling molecules, including E-cadherin, Collagen I, α-SMA, Smad3/1/5, and pSmad3/1/5, after the experiment. For signaling molecules, the establishment of an atrial fibrillation model significantly up-regulated pSmad3 and down-regulated pSmad1/5. However, the above trend can be antagonized by both low- and high-dose BMP-7, while the effect of BMP-7 was significantly inhibited by Smad1/5 siRNA (all *P*\<0.05, [Table 6](#t6-medscimonit-22-3457){ref-type="table"}, [Figure 8](#f8-medscimonit-22-3457){ref-type="fig"}). Moreover, BMP-7 and Smad1/5 siRNA slightly affected the expression of Smad3 and Smad1/5. Both BMP-7 and Smad1/5 siRNA significantly influenced fibrosis markers, including E-cadherin, collagen I and α-SMA. Significant differences between each of the 2 groups in the 5 groups were observed (all *P*\<0.05, [Figure 8](#f8-medscimonit-22-3457){ref-type="fig"}).

Tissues in the model group had lower E-cadherin and higher collagen I and α-SMA expressions, while BMP-7 treatments up-regulated E-cadherin and down-regulated collagen I and α-SMA expressions. Therefore, Smad1/5 can reverse the effects of BMP-7 on these expressions and *in vivo* results agreed with *in vitro* results.

Discussion
==========

Our study investigated the effect of TGF-β and BMP-7 on myocardial fibrosis. We found that smad3 siRNA could suppress myocardial fibrosis induced by TGF-β and BMP-7 could also antagonize myocardial fibrosis induced by TGF-β, but the effect of BMP-7 was decreased when Smad1/5 siRNA was transfected. Our results from the atrial fibrillation model in mice show that BMP-7 elevated the cardiac function parameters in a dose-dependent manner and its protective effect in cardiac functions was inhibited when Smad1/5 siRNA was co-transfected.

A previous study has shown that TGF-β can promote procollagen formation and ECM synthesis, thus resulting in myocardial fibrosis \[[@b24-medscimonit-22-3457]\]. Stimulation of TGF-β can activate fibroblasts, which were thereby transformed into myofibroblasts. Myofibroblasts, which are characterized by the acquired expression of α-SMA, are key effector cells in fibrotic states \[[@b25-medscimonit-22-3457]\]. Important elements for evaluating myofibroblast differentiation include the expression of α-SMA and the secretion of extracellular matrix, such as collagen and fibronectin \[[@b26-medscimonit-22-3457]\]. More importantly, the expression of α-SMA and collagen I are both coordinately regulated by TGF-β \[[@b27-medscimonit-22-3457]\]. As suggested by our study, the expression of α-SMA and collagen I were both increased in myocardial fibroblasts when SD mice were treated with TGF-β. Furthermore, TGF-β exerts an important role in EMT, in which the Smad signaling pathway is involved \[[@b28-medscimonit-22-3457]\]. Smad expression exhibits a distinct level in fibrosis tissues and Smad3 exerted its influence on regulating pathological fibrotic disorders (e.g., cystic fibrosis, scleroderma, and cirrhosis) induced by TGF-β \[[@b29-medscimonit-22-3457]\]. Analogously, we demonstrated that Smad3 expression was increased in cardiac fibrosis when TGF-β treatments were introduced. As a result, both Smad3 siRNA and TGF-β were introduced in our experiment, which revealed that α-SMA and collagen I were decreased to a level between the control and TGF-β treatment group. Therefore, Smad3 siRNA can partially reverse the effect of TGF-β on α-SMA and collagen I.

It has been reported that BMP-7 was able to reverse EMT in proximal tubular cells \[[@b30-medscimonit-22-3457]\], and there are several studies showing a negative relationship between BMP-7 and fibrosis of different organs. BMP-7 plays anti-inflammatory and anti-fibrogenic roles in the progression of chronic hepatitis as well as an anti-fibrotic role in the formation of hepatic fibrosis \[[@b31-medscimonit-22-3457]\]. Furthermore, BMP-7 prevents fibrosis formation in the kidneys \[[@b8-medscimonit-22-3457]\] and the expression of BMP-7 was largely decreased when idiopathic pulmonary fibrosis was triggered \[[@b32-medscimonit-22-3457]\]. In our study, the addition of BMP-7 improved the cardiac function of mice in which the AF model was constructed, indicating that BMP-7 plays a protective role in myocardial fibrillation. Because it has also been reported that the activation of type I BMP receptor phosphorylated both Smad1 and Smad5 \[[@b33-medscimonit-22-3457]\], we examined the expression of Smad1/5 and pSmad1/5. When BMP-7 was added to myocardial fibroblasts treated with TGF-β, pSmad1/5 was markedly increased. As suggested by the atrial fibrillation model, cardiac functions could be restored with the addition of Smad1/5 siRNA. All of the above results suggest that BMP-7 plays a protective role in myocardial fibrillation via its influence on the Smad1/5 pathway.

In addition to the studied BMP-7, TGF-β and Smads, there are many other cardiac biomarkers that should be emphasized, including interleukin-3 (IL-3), IL-4, IL-6, nuclear factor-κB (NF-κB) kinase (IKK) complex, and suppression of tumorigenicity 2 (ST2) \[[@b34-medscimonit-22-3457]--[@b37-medscimonit-22-3457]\]. Of note, ST2 mainly functions to protect myocardium viability, which suffers enormous pressure; ST2 is considered to be a reliable cardiac marker \[[@b29-medscimonit-22-3457]\]. Downstream factors of TGF-β/Smad, such as dual-specificity phosphatase 9 (DUSP9), mitogen-activated protein kinase (MAPK), and T-box protein 3 (TBX3), also need to be studied because their modifications are the final results of regulated TGF-β/Smad expressions and they could be desirable treatment targets for myocardial fibrosis \[[@b38-medscimonit-22-3457]--[@b40-medscimonit-22-3457]\].

Conclusions
===========

Although previous studies have shown that BMP-7 can antagonize fibrosis in different tissues and organs, it is unknown whether BMP-7 has similar effects on myocardial fibrosis. Our study shows that BMP-7 plays a positive role in myocardial fibrosis through the TGF-β/Smads signaling pathway and it is able to improve the shape, arrangement, and function of myocardial fibroblasts. Nevertheless, the specificity and efficacy of BMP-7 treatment for AF remain unknown and potential adverse effects of treatment using BMP-7 should be further investigated.

**Source of support:** Departmental sources

![Immunohistochemistry results of isolated myocardial fibroblasts, ×400. (**A**) Vimentin was stained as brown particles in cell cytoplasm. (**B**) Negative result of immunohistochemistry for SMA.](medscimonit-22-3457-g001){#f1-medscimonit-22-3457}

![Cell activity was up-regulated by TGF-β in myocardial fibroblasts. (**A**) The effect of different concentrations of TGF-β on cell activity. \* *P*\<0.05 versus control group; ^\#^ *P*\<0.05 versus 10^−8^ mol/L group; ^&^ *P*\<0.05 versus 10^−7^ mol/L group. (**B**) The effect of different treatment times of TGF-β on cell activity. \* *P*\<0.05 versus 0 h group; ^\#^ *P*\<0.05 versus 6 h group; ^&^ *P*\<0.05 versus 12 h group. Data are presented as mean ±SD for 3 independent experiments.](medscimonit-22-3457-g002){#f2-medscimonit-22-3457}

![Expression levels of fibrosis markers in myocardial fibroblasts treated with TGF-β1 and Smad3 siRNA. (**A**) Western blot analysis of fibrosis markers in cells of different groups normalized to β-actin. (**B--F**) Quantitative data for protein levels of fibrosis markers in cells with different controls. Data are presented as mean ±SD for 3 independent experiments. \* *P*\<0.05 versus control group, ^\#^ *P*\<0.05 versus TGF-β1 group.](medscimonit-22-3457-g003){#f3-medscimonit-22-3457}

![Expression levels of fibrosis markers in myocardial fibroblasts treated with TGF-β1, BMP-7, and Smad1/5 siRNA. (**A**) Western blot analysis of fibrosis markers in cells of different groups normalized to β-actin. (**C--H**) Quantitative data for protein levels of fibrosis markers in cells with different controls. Data are presented as means ±SD for 3 independent experiments. \* *P*\<0.05 versus TGF-β1 group, ^\#^ *P*\<0.05 versus TGF-β1 + BMP-7 group.](medscimonit-22-3457-g004){#f4-medscimonit-22-3457}

![Representative telemetry ECG results showing spontaneous atrial ectopy in the model group (**B**), while no AF signals were observed in the control group (**A**).](medscimonit-22-3457-g005){#f5-medscimonit-22-3457}

![Results of cardiac functions with echocardiographic measurement. Data are presented as mean ±SD for 3 independent experiments. EF -- ejection fraction; FS -- fractional shortening; LVESD -- left ventricular end-systolic dimension; LVEDD -- left ventricular end-diastolic dimension. \* *P*\<0.05 versus control group; ^\#^ *P*\<0.05 versus model group; ^&^ *P*\<0.05 versus model + medicine group; ^@^ *P*\<0.05 versus transfection control group.](medscimonit-22-3457-g006){#f6-medscimonit-22-3457}

![HE staining of fibrous tissue in atria of rats. (**A--E**) Showed the results of rats in control group, model group, low-dose BMP-7 group, high-dose BMP-7 group, and high-dose BMP-7 + Smad1/5 siRNA group in order (×400).](medscimonit-22-3457-g007){#f7-medscimonit-22-3457}

![Expression levels of fibrosis markers in mice with different treatments. (**A**) Western blot analysis of fibrosis markers in cardiac tissues of different groups normalized to β-actin. (**B--H**) Quantitative data protein level of fibrosis markers in tissues with different control. Data are presented as mean ±SD for 3 independent experiments. \* *P*\<0.05 versus control group; ^\#^ *P*\<0.05 versus model group; ^&^ *P*\<0.05 versus model + medicine group; ^@^ *P*\<0.05 versus transfection control group.](medscimonit-22-3457-g008){#f8-medscimonit-22-3457}

###### 

Influence of different density of TGF-β1 for cell activity.

             Control       10^−8^ mol/L   10^−7^ mol/L                                                      10^−6^ mol/L                                                                                                                                                             10^−5^ mol/L
  ---------- ------------- -------------- ----------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  OD value   0.116±0.007   0.133±0.007    0.148±0.007[\*](#tfn1-medscimonit-22-3457){ref-type="table-fn"}   0.175±0.005[\*](#tfn1-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn2-medscimonit-22-3457){ref-type="table-fn"}[&](#tfn3-medscimonit-22-3457){ref-type="table-fn"}   0.190±0.007[\*](#tfn1-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn2-medscimonit-22-3457){ref-type="table-fn"}[&](#tfn3-medscimonit-22-3457){ref-type="table-fn"}

*P*\<0.05 versus control group;

*P*\<0.05 versus 10^−8^ mol/L group;

*P*\<0.05 versus 10^−7^ mol/L group.

###### 

Influence of different time of TGF-β1 for cell activity.

             0 h           6 h           12 h                                                              24 h                                                                                                                  48 h
  ---------- ------------- ------------- ----------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  OD value   0.103±0.013   0.122±0.003   0.135±0.007[\*](#tfn4-medscimonit-22-3457){ref-type="table-fn"}   0.156±0.015[\*](#tfn4-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn5-medscimonit-22-3457){ref-type="table-fn"}   0.169±0.011[\*](#tfn4-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn5-medscimonit-22-3457){ref-type="table-fn"}[&](#tfn6-medscimonit-22-3457){ref-type="table-fn"}

*P*\<0.05 versus 0 h group;

*P*\<0.05 versus 6 h group;

*P*\<0.05 versus 12 h group.

###### 

Influence of TGF-β1 and Smad3 inhibitors on fibrosis markers.

  Group        Control group   TGF-β1 group                                                    TGF-β1+Smad3 siRNA group
  ------------ --------------- --------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------
  E-cadherin   1.01±0.04       0.34±0.02[\*](#tfn7-medscimonit-22-3457){ref-type="table-fn"}   0.74±0.12
  Collagen I   1.01±0.07       2.24±0.17[\*](#tfn7-medscimonit-22-3457){ref-type="table-fn"}   1.32±0.09[\#](#tfn8-medscimonit-22-3457){ref-type="table-fn"}
  α-sma        0.98±0.05       8.25±0.96[\*](#tfn7-medscimonit-22-3457){ref-type="table-fn"}   2.34±0.48[\*](#tfn7-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn8-medscimonit-22-3457){ref-type="table-fn"}
  Smad3        1.03±0.05       1.07±0.07                                                       0.75±0.04
  pSmad3       1.04±0.11       2.26±0.24[\*](#tfn7-medscimonit-22-3457){ref-type="table-fn"}   1.57±0.19[\#](#tfn8-medscimonit-22-3457){ref-type="table-fn"}

*P*\<0.05 versus control group;

*P*\<0.05 versus TGF-β1 group.

###### 

Influence of BMP-7 and Smad1/5 inhibitors on fibrosis markers.

  Group        TGF-β1 group   TGF-β1+BMP-7 group                                              TGF-β1+BMP-7+ Smad1/5 siRNA group
  ------------ -------------- --------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  E-cadherin   1.01±0.05      2.12±0.14[\*](#tfn9-medscimonit-22-3457){ref-type="table-fn"}   1.47±0.12[\*](#tfn9-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn10-medscimonit-22-3457){ref-type="table-fn"}
  Collagen I   1.02±0.07      0.45±0.09[\*](#tfn9-medscimonit-22-3457){ref-type="table-fn"}   0.72±0.10[\*](#tfn9-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn10-medscimonit-22-3457){ref-type="table-fn"}
  a-sma        0.98±0.04      0.41±0.07[\*](#tfn9-medscimonit-22-3457){ref-type="table-fn"}   0.74±0.06[\*](#tfn9-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn10-medscimonit-22-3457){ref-type="table-fn"}
  Smad3        1.01±0.07      0.97±0.06                                                       1.08±0.06
  pSmad3       1.03±0.06      0.68±0.07[\*](#tfn9-medscimonit-22-3457){ref-type="table-fn"}   0.82±0.08[\*](#tfn9-medscimonit-22-3457){ref-type="table-fn"}
  Smad1/5      0.97±0.04      1.02±0.07                                                       0.87±0.04
  pSmad1/5     1.02±0.04      2.17±0.14[\*](#tfn9-medscimonit-22-3457){ref-type="table-fn"}   1.47±0.09[\*](#tfn9-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn10-medscimonit-22-3457){ref-type="table-fn"}

*P*\<0.05 versus TGF-β1 group;

*P*\<0.05 versus TGF-β1 + BMP-7 group.

###### 

Results of echocardiographic measurement of atrial fibrillation model mice.

  Group        Control      Model                                                            Low dose BMP-7                                                                                                         High dose BMP-7                                                                                                                                                            High dose BMP-7 + Smad1/5 siRNA
  ------------ ------------ ---------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  EF/%         63.45±3.21   27.3±4.83[\*](#tfn12-medscimonit-22-3457){ref-type="table-fn"}   37.94±3.14[\*](#tfn12-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn13-medscimonit-22-3457){ref-type="table-fn"}   50.17±3.82[\*](#tfn12-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn13-medscimonit-22-3457){ref-type="table-fn"}[&](#tfn14-medscimonit-22-3457){ref-type="table-fn"}   30.21±3.01[\*](#tfn12-medscimonit-22-3457){ref-type="table-fn"}[&](#tfn14-medscimonit-22-3457){ref-type="table-fn"}[@](#tfn15-medscimonit-22-3457){ref-type="table-fn"}
  FS(%)        36.3±2.4     13.6±3.22[\*](#tfn12-medscimonit-22-3457){ref-type="table-fn"}   20.14±3.31[\*](#tfn12-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn13-medscimonit-22-3457){ref-type="table-fn"}   25.73±3.32[\*](#tfn12-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn13-medscimonit-22-3457){ref-type="table-fn"}[&](#tfn14-medscimonit-22-3457){ref-type="table-fn"}   15.24±3.12[\*](#tfn12-medscimonit-22-3457){ref-type="table-fn"}[&](#tfn14-medscimonit-22-3457){ref-type="table-fn"}[@](#tfn15-medscimonit-22-3457){ref-type="table-fn"}
  LVESD (mm)   3.0±0.32     5.78±0.16                                                        5.04±0.12                                                                                                              3.74±0.13                                                                                                                                                                  5.67±0.14
  LVEDD (mm)   5.12±0.17    6.45±0.20                                                        6.12±0.21                                                                                                              5.49±0.24                                                                                                                                                                  6.28±0.18

EF -- ejection fraction; FS -- fractional shortening; LVESD -- left ventricular end-systolic dimension; LVEDD -- left ventricular end-diastolic dimension.

*P*\<0.05 versus control group;

*P*\<0.05 versus model group;

*P*\<0.05 versus model + medicine group;

*P*\<0.05 versus transfection control group.

###### 

Expression level of fibrosis markers of model mice.

  Group        Control     Model                                                            Low dose BMP-7                                                                                                        High dose BMP-7                                                                                                                                                           High dose BMP-7 + Smad1/5 siRNA
  ------------ ----------- ---------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  E-cadherin   1.01±0.04   0.21±0.02[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}   0.46±0.03[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}   0.57±0.04[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}                                                       0.40±0.03[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}
  Collagen I   1.02±0.05   5.01±0.42[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}   3.60±0.15[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}   3.26±0.15[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}[&](#tfn18-medscimonit-22-3457){ref-type="table-fn"}   4.77±0.34[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}[&](#tfn18-medscimonit-22-3457){ref-type="table-fn"}[@](#tfn19-medscimonit-22-3457){ref-type="table-fn"}
  a-sma        1.01±0.07   2.64±0.22[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}   1.99±0.15[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}   1.71±0.17[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}[&](#tfn18-medscimonit-22-3457){ref-type="table-fn"}   2.23±0.22[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}[&](#tfn18-medscimonit-22-3457){ref-type="table-fn"}[@](#tfn19-medscimonit-22-3457){ref-type="table-fn"}
  Smad3        1.00±0.06   1.23±0.07[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}   0.94±0.05[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}                                                        0.87±0.05[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}                                                                                                            1.12±0.07[&](#tfn18-medscimonit-22-3457){ref-type="table-fn"}[@](#tfn19-medscimonit-22-3457){ref-type="table-fn"}
  pSmad3       0.98±0.05   4.89±0.21[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}   2.74±0.19[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}   2.36±0.17[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}[&](#tfn18-medscimonit-22-3457){ref-type="table-fn"}   3.97±0.20[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}[&](#tfn18-medscimonit-22-3457){ref-type="table-fn"}[@](#tfn19-medscimonit-22-3457){ref-type="table-fn"}
  Smad1/5      1.01±0.06   0.94±0.04                                                        1.07±0.06                                                                                                             1.17±0.08[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}                                                                                                            1.04±0.05
  pSmad1/5     0.99±0.05   0.43±0.03[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}   0.57±0.04[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}                                                        0.78±0.04[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}[\#](#tfn17-medscimonit-22-3457){ref-type="table-fn"}[&](#tfn18-medscimonit-22-3457){ref-type="table-fn"}   0.47±0.03[\*](#tfn16-medscimonit-22-3457){ref-type="table-fn"}[@](#tfn19-medscimonit-22-3457){ref-type="table-fn"}

*P*\<0.05 versus control group;

*P*\<0.05 versus model group;

*P*\<0.05 versus model + medicine group;

*P*\<0.05 versus transfection control group.
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